tial" or "continue," the negative of such
terms, or other comparable terminology. These statements are only
predictions. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should not be
regarded as a representation by the Company, or any other person, that such
forward-looking statements will be achieved. We undertake no duty to update
any of the forward-looking statements, whether as a result of new
information, future events, or otherwise. In light of the foregoing,
readers are cautioned not to place undue reliance on such forward-looking
statements.
Contact:
William J. Garner, MD
bill@inverseon.com
http://www.inverseon.com
(212) 222-1188
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
'/>"/>SOURCE Inverseon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Landfill mining reduces environmental impact of growing waste2.
Landfill mining reduces environmental impact of growing waste3.
New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain4.
ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests5.
Heavier hydrogen on the atomic scale reduces friction6.
Genmab Announces Encouraging Preclinical Data for ofatumumab7.
Arius Features Preclinical Data on Antibody Candidates at Two Conferences8.
Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 20079.
Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC10.
Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC11.
Arpida Presents Preclinical Data on AR-2474 at ICAAC